PTO/SB/08A & PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W&	K Substitute for Form PTO-S8	VOSA, whi	ch is a US PTO	Complet if Kn wn			
Substitute for for	orm 1449A/PTO and 1449B/PT	TO		Application Number	10/049,988		
INFOR	RMATION DI	SCI	OSURE	Filing Date	August 21, 2000		
				First Named Inventor	Jürgen MARKL, et al.		
STATEMENT BY APPLICANT				Art Unit	Not Yet Assigned		
	(use as many she	ets as	necessary)	Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	GKS 102.0 US (7911/86349)		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number - Kind Code² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cotumns, Lines, Where Relevant Passages or Relevant Figures Appear	
mm	A1	5,888,775	03/30/1999	Tal, et al.		
	A2	5,831,033	11/03/1998	Zetter, et al.		
1/	A3	5,021,560	06/04/1991	Montreuil et al		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6		
Sinn	A4	WO 00/55192	09/21/2000	Biosyn Arzneimittel GMBH				
Smm	A5	WO 94/11019	05/26/1994	Zonagen, Inc.				
mm	A6	EP-0 244 295 A1	11/04/1987	Institut Pasteur		X		
Site	A7-	EP-0.252 829 A1	01/13/1999	Institut Pasteur		X		
Smm	A8	EP 0 621 039 A1	10/26/1994	Akzo Nobel N.V.				

Abstranty Abstranty Abs. only

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	_,
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ ⁵
Smm	A9	LIEB et al., "Structures of two molluscan hemocyanin genes: Significance for gene evolution", PNAS 98(8):4546-4551 (04/2001)	
Sum	A10	HAMILTON, et al., "Periodate-Sensitive Immunological Cross-Reactivity Between Keyhole Limpet Haemocyanin (KLH) and Serodiagnostic Schistosoma Mansoni Egg Antigens," Parasitology, 118:83-89 (01/1999)	
Smrn	A11	MILLER, et al., "Sequence of the Octopus Dofleini Hemocyanin Subunit: Structural and Evoluntionary Implications," J. Mol. Biol. 278:827-842 (01/1998)	
Sura	413	STOEVA, et al., "Primary Structure and Unusual Carbohydrate Moiety of Functional Unit 2-c of Keyhole Limpet Hemocyanin (KLH),"Biochimica et Biophysica Acta,, 1435:94-109 (09/1999)	
Sum	A13	GEBAUER, et al., "Keyhole Limpet Hemocyanin Type 2 (KLH2): Detection and Immunolocalization of a Labile Functional Unit h, Journal of Structural Biology 128:280-286 (10/1999)	
Eun	A14	HARRIS, et al., "Immunoelectron Microscopy of Hemocyanin from the Keyhole Limpet (Megathura Crenulata): A Parallel Subunit Model," Journal of Structural Biology, 111:96-104 (11/1993)	

Evaminar	Τ.			l Date			
Examme	\	~~ ^	000	1 22.0	<u>ا</u>	No. 1	200
Cianoturo	Surare	$\Lambda \chi \chi$	U VOANO (Considered	1117	11 YLACK	(CI)
Signature	The Aire	11.7	1 000 10-4	00110100100	<u> </u>	1 00:01	<u> </u>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A & PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known 10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO Substitute for form 1449A/PTO and 1449B/PTO **Application Number** 10/049,988 **Filing Date** August 21, 2000 INFORMATION DISCLOSURE First Named Inv ntor Jürgen MARKL, et al. STATEMENT BY APPLICANT **Art Unit** Not Yet Assigned **Examiner Name** Not Yet Assigned (use as many sheets as necessary) Sheet 2 of 2 Attorney Docket Number GKS 102.0 US (7911/86349)

. ^^^	A15	CARRERA, et al., "Cocaine Vaccines: Antibody Protection Against Relapse in a Rat
1		Model,"Proc. Natl. Acad. Sci, USA, 97(11):6202-6206 (05/23/2000)
	A16	SÖHNGEN, et al., "Mass Determination, Subunit Organization and Control of
		Oligomerization States of Keyhole Limpet Hemocyanin (KLH)," Eur. J. Biochem.,
		248:602-624 (05/1997)
	A17	CARRERA, et al., "Suppression of Psychoactive Effects of Cocaine by Active
1		Immunization," Nature, 378:727-730 (12/14/1995)
	A18	LIEB, et al., "The Sequence of a Gastropod Hemocyanin (HtH1 from Haliotis
1 1		tuberculata), Journal of Biological Chemistry, 275(8):5675-5681 (02/25/2000)
	A19	LIEB, et al., "Subunit Organization of the Abalone Haliotis tuberculata Hemocyanin
1 1		Type 2 (HtH2), and the cDNA Sequence Encoding its Functional Units d, e, f, g and h,"
		Eur. J. Biochem. 265:134-144 (07/1999)
	A20	SWERDLOW, et al., "Keyhole Limpet Hemocyanin: Structural and Functional
1 1		Characterization of Two Different Subunits and Multimers," Comp. Biochem. Physiol.
		113B (3):537-548 (1996)
1	A21	KELLER, et al., "Abalone (Haliotis tuberculata) Hemocyanin Type 1 (HtH1):
- {		Organization of the 400 kDa Subunit, and Amino Acid Sequence of its Functional
		Units f, g and h," Eur. J. Biochem. 264:27-39 (05/1999)
[]	A22	HARRIS, et al., "Keyhole Limpet Haemocyanin (KLH): Purification of Intact KLH1
1		Through Selective Dissociation of KLH2," Micron, 26(3):201-212 (02/1995)
	A23	GEBAUER, et al., "Quaternary Structure, Subunits and Domain Patterns of Two
- }		Discrete Forms of Keyhole Limpet Hemocyanin: KLH1 and KLH2," Zoology 98:51-68
ll		(02/1994)
	A24	DREXEL, et al., "Complete Amino-Acid Sequence of a Functional Unit from a
11.1	:	Molluscan Hemocyanin (Helix pomatia)," Biol. Chem. Hoppe-Seyler 368:617-635
V		(06/1987)
}		
1		
1		
-,,		
ļ		

Examiner	Ι,		Date	1
Signature	Ausare	m. Wlayer	Considered	10 March 2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional), ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3), ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.